Renal cell carcinoma trends in Latvia: incidence, mortality, and survival rates. Population-based study
Renal cell carcinoma trends in Latvia: incidence, mortality, and survival rates. Population-based study
复制标题
拉脱维亚肾细胞癌趋势：发病率、死亡率和生存率。
DOI：
--
复制
发表时间：
2019
影响因子：
1.2
通讯作者：
V. Lietuvietis
中科院分区：
文献类型：
--
作者：
M. Jakubovskis;U. Kojalo;Baiba Steinbrekera;J. Auzins;D. Kirilovas;V. Lietuvietis
导言据报道，包括拉脱维亚在内的波罗的海国家是世界上肾细胞癌发病率和死亡率最高的国家之一。然而，提供的数据往往没有特定阶段的分层，这使得对整个肾癌诊断和生存趋势的评估具有挑战性。材料和方法我们收集了1997-2016年间所有新诊断的肾癌患者的数据，这些患者来自国家基于人口的癌症登记。我们使用Joinpoint分析来分析肾癌的发病率、死亡率和生存趋势。Kaplan-Meier分析用于计算5年和10年的癌症特定生存率。结果新诊断肾细胞癌7893例。年龄标化发病率(每10万人)略有上升，从1997年的8.9上升到2016年的9.8。发病率趋势无明显变化。早期肾癌的发现率以每年5.4%的速度增长。AS死亡率(每10万人中的死亡率)从1997年的4.9下降到2016年的3.9，但在统计上没有显著变化。女性和60-69岁年龄组的死亡率显著下降。5年癌症特定生存率从1997-2001年的55.1%上升到2007-2011年的66.6%。10年期社区卫生服务率从1997-2001年的49.1%上升到2002-2006年的56.5%。结论在研究期间，肾癌发病率增加，总体死亡率没有变化。与世界其他地区类似，早期诊断的肾癌发病率增加，5年和10年生存率提高。
Introduction Baltic States including Latvia are reported as having one of the highest renal cell carcinoma (RCC) incidence and mortality rates in the world. However, data are often presented without stage-specific stratification, making assessment of the overall RCC diagnosis and survival trends challenging. Material and methods We collected data on all newly diagnosed RCC patients from the national population-based cancer registry between 1997 and 2016. We analyzed RCC incidence, mortality and survival trends using Joinpoint analysis. Kaplan-Meier analysis was performed for 5- and 10-year cancer specific survival rate calculations. Results There were a total of 7893 patients with newly diagnosed RCC. The age standardized (AS) incidence rate (per 100,000) increased slightly from 8.9 in 1997 to 9.8 in 2016. There were no specific changes in the incidence rate trend. Detection of early stage RCC increased by 5.4% annually. The AS mortality rates (per 100,000) decreased from 4.9 in 1997 to 3.9 in 2016, however, it did not reach a statistically significant change. The mortality rates decreased significantly in females and in the age group of 60-69 years. The 5-year cancer specific survival (CSS) rate increased from 55.1% in 1997-2001 to 66.6% in years 2007–2011. The 10-year CSS rate increased from 49.1% in 1997–2001 to 56.5% in years 2002–2006. Conclusions During the study period, RCC incidence rates increased and overall mortality rates did not change. Similar to the rest of the world, the incidence of RCC diagnosed at an earlier stage increased and 5- and 10-year survival rates improved.
DOI：
10.1016/j.juro.2008.06.037
发表时间：
2008-10
期刊：
The Journal of urology
影响因子：
--
作者：
Thompson RH;Ordonez MA;Iasonos A;Secin FP;Guillonneau B;Russo P;Touijer K
通讯作者：
Touijer K